DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
NCT ID: NCT04290676
Last Updated: 2021-05-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
527 participants
OBSERVATIONAL
2019-11-13
2020-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
NCT05191706
Study of Dexycu in Treating Intraocular Inflammation
NCT06429306
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
NCT06497699
A Study for Post op Inflammation After Cataract Surgery
NCT05665270
Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes
NCT04977427
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DEXYCU (dexamethasone intraocular suspension) 9%.
DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
DEXYCU (dexamethasone intraocular suspension) 9%.
DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DEXYCU (dexamethasone intraocular suspension) 9%.
DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EyePoint Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dario Paggiarino, MD
Role: PRINCIPAL_INVESTIGATOR
Senior Vice President, Chief Medical Officer, EyePoint Pharmaceuticals
Keyur Patel, PharmD
Role: STUDY_CHAIR
Vice President, Medical Affairs, EyePoint Pharmaceuticals
Flavio Leonin, Jr., MD
Role: STUDY_DIRECTOR
Senior Manager, Clinical Affairs, EyePoint Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eye Center South Locations
Dothan, Alabama, United States
Inland Eye Specialists
Hemet, California, United States
Harvard Eye Associates
Laguna Hills, California, United States
Coastal Vision Medical Group
Orange, California, United States
North Bay Eye Associates, Inc.
Rohnert Park, California, United States
The Eye Associates of Manatee, LLP
Bradenton, Florida, United States
Eye Physicians of Pinellas, PA, dba The Eye Institute of West Florida
Largo, Florida, United States
Jacksoneye, SC
Lake Villa, Illinois, United States
Hauser-Ross Eye Institute
Oak Brook, Illinois, United States
Price Vision Group
Indianapolis, Indiana, United States
Physicians Eyecare Center
Baltimore, Maryland, United States
Discover Vision Centers
Independence, Missouri, United States
Silverstein Eye Centers
Kansas City, Missouri, United States
Tekwani Vision Center
St Louis, Missouri, United States
Surgery Center of Central New Jersey
Pennington, New Jersey, United States
SightMD, PLLC
Hauppauge, New York, United States
New York Eye Surgery Center
The Bronx, New York, United States
Island Eye Surgicenter
Westbury, New York, United States
Wills Surgery Center
Jenkintown, Pennsylvania, United States
VRF Eye Specialty Group
Memphis, Tennessee, United States
Valley Retina Institute, PA
McAllen, Texas, United States
The Eye Centers of Racine and Kenosha
Racine, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DEXYCU Retrospective Study 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.